Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.

H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...

A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Retired tennis star Serena Williams said she underwent a procedure to remove a benign branchial cyst "the size of a small ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

TenNor Therapeutics has raised over 300 million yuan ($41 million) in a series E round, led by AMR Action Fund, to advance ...

US stock futures traded in a stable manner Wednesday, steadying after the previous season’s tech-inspired losses as quarterly ...